Skip to main content

Table 1 Baseline patient characteristics

From: Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis

All patients with follow-up 405 (92.5)
Time to follow-up [days] 1591 (1490–1739)
Gender, female 177 (43.7)
Age [years] 47.9 (36.9-60.8)
Referring physician  
Inpatients 222 (54.8)
Outpatients referred by cardiologists 154 (38.0)
Outpatients referred by general practitioners 29 (7.2)
Primary cardiac symptoms leading to CMR (multiple possible)  
Reduced LVEF 82 (20.2)
Pericardial effusion 6 (1.5)
ECG abnormality 131 (32.3)
Palpitations 92 (22.7)
Dyspnea 137 (33.8)
Angina/Chest pain 217 (53.6)
Abnormal fatigue 96 (23.8)
Wall motion abnormality 17 (4.2)
Ventricular arrythmias/Extrasystoles 45 (11.1)
Aborted SCD 6 (1.5)
Viral prodrome/history of infectious symptoms 130 (32.1)
Atrial fibrillation 50 (12.4)
Elevated troponin 38 (9.4)
Coronary angiography performed 205 (50.6)
EMB performed 78 (20.5)
Histopathological myocarditis in EMB 53 (68.8)
PVB19 29 (37.7)
HHV6 12 (15.6)
Double infection PVB19/HHV6 10 (13.0)
EBV 1 (1.3)
CMR imaging parameters  
LVEF [%] 62.5 (55.0-68.0)
LV-EDV [ml] 137 (110–164)
LV-ESV [ml] 50 (36–72)
LVEDD [mm] 50 (46.0-54.5)
Pericardial effusion present 76 (18.8)
LGE present 114 (28.3)
Final diagnosis based on CMR  
No cardiac pathology 225 (55.6)
Myocarditis 116 (28.8)
Other cardiac pathology 63 (15.6)
  1. Values shown are n (%) or medians and IQR = interquartile range (25th-75th percentiles) CMR, cardiovascular magnetic resonance; LVEF, left ventricular ejection fraction; SCD, sudden cardiac death, EMB, endomyocardial biopsy, PVB19, parvovirus B 19; HHV6, human herpes virus 6; EBV, ebstein-barr virus; CMR, cardiovascular magnetic resonance; EDV, enddiastolic volume; ESV, endsystolic volume; LVEDD, left ventricular enddiastolic diameter; LGE, late gadolinium enhancement.